Author:
Vahl Julius Malte,Friedrich Juliane,Mittler Susanne,Trump Sonja,Heim Lisanne,Kachler Katerina,Balabko Liubov,Fuhrich Nicole,Geppert Carol-Immanuel,Trufa Denis Iulian,Sopel Nina,Rieker Ralf,Sirbu Horia,Finotto Susetta
Publisher
Springer Science and Business Media LLC
Reference51 articles.
1. Almatroodi S, McDonald C, Darby I, Pouniotis D (2016) Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron 9 (1): 1–11.
2. Antonia S, Rizvi N, Brahmer J, Ou S-H, Khleif SN, Hwu W-J, Gutierrez M, Schoffski P, Hamid O, Weiss J (2016) Abstract A047: Safety and clinical activity of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Cancer Immunol Res 4 (1 Supplement): A047–A047.
3. Banat G-A, Tretyn A, Pullamsetti SS, Wilhelm J, Weigert A, Olesch C, Ebel K, Stiewe T, Grimminger F, Seeger W (2015) Immune and inflammatory cell composition of human lung cancer stroma. PLoS One 10 (9): e0139073.
4. Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit E, Syrigos K, Stahel R (2014) 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 25 (8): 1475–1484.
5. Chaudhry A, Samstein RM, Treuting P, Liang Y, Pils MC, Heinrich J-M, Jack RS, Wunderlich FT, Brüning JC, Müller W (2011) Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity 34 (4): 566–578.
Cited by
78 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献